Cognitive Change
Conditions
Keywords
Probiotic, Fermented milk
Brief summary
Single-center, randomized, double-blind, placebo-controlled clinical study with two study groups. One group will consume a product with functional ingredients and the other group will consume a placebo product. will consume a placebo product.
Detailed description
When individuals are included in the study they will be randomized in equal proportion to one of the 2 groups of the study. The randomization will be stratified by age taking into account 2 strata (1:1). The first stratum corresponds to an age range of 18 to 40 years and the second stratum to an age range of 41 to 60 years. The subject must consume the product for 8 weeks and will have a visit 4 weeks later as a follow-up of the study. At the visits the subject will perform a series of cognitive tests and the intestinal microbiota will be evaluated.
Interventions
DIETARY_SUPPLEMENTProbiotic
Fermented milk product containing a probiotic
DIETARY_SUPPLEMENTPlacebo
Product with identical characteristics to the experimental product.
Sponsors
Universidad Católica San Antonio de Murcia
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women aged 18-60 years. * Individuals with a diagnosis of mild-moderate stress according to the Cohen's perceived stress scale perceived stress scale (PSS-10). * Subjects with poor adherence to the Mediterranean diet according to the PREDIMED questionnaire (value below 9 points)\*. * BMI between 19 and 30 kg/m2.
Exclusion criteria
* Present chronic and/or acute digestive pathologies that may interfere in the absorption of nutrients (inflammatory intestinal diseases, inflammatory bowel absorption of nutrients (inflammatory intestinal diseases, etc.), etc.) * Intake of probiotics and/or prebiotics in the four weeks prior to the inclusion in the study. * Individuals who are on antibiotic treatment or have completed an antibiotic treatment during the 30 days prior to inclusion in the study. * Vegan diet. * Being taking any type of supplementation that interacts with cognitive level in the 2 weeks prior to the start of the study. * Individuals who had taken or were taking any medications or supplementation for stress management, mood, or to induce sleep in the 2 weeks prior to the start of the study. * A history of allergic hypersensitivity or poor tolerance to any component of the products under study. * Consumption of 2 or more Standard Drink Units (UBE) daily or 17 weekly in women, or consume 4 or more UBE daily or 28 weekly in men. * Smoking and non-smoking subjects who have modified their nicotinic habits in the last 3 months. * Pregnant or lactating women. * Been participating or have participated in another clinical trial in the 2 months prior to the study to the study. * Unwillingness or inability to comply with the procedures of the clinical trial. * Subjects with any diagnosed psychiatric disorder. * Subjects whose condition makes them ineligible for the study in accordance with the criteria of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive performance | Change in baseline cognitive performance after 8 weeks of consumption | COMPASS cognitive test panel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mood profile | Day 1, at 4 and 8 weeks later | POMS test |
| Depression, Anxiety and Stress | Day 1, at 4 and 8 weeks later | DASS21 test |
| State of mind | Day 1, at 4 and 8 weeks later | PANAS test |
| Stress status using VAS scale | Day 1, at 4 and 8 weeks later | Stress status on the day of the visit |
| Sleep efficiency | It will be measured for 3 days, before starting the consumption of the product, after 30 days of consumption and at the end of consumption (60 days). | Measured by accelerometry, with Actigraph wGT3X-BT |
| Sleep quality | Day 1, at 4 and 8 weeks later | Pittsburgh test |
| Perceived Stress Scale | Day 1, at 4 and 8 weeks later | PSS-14 test |
| Adverse events | At 4 weeks, 8 and 12 weeks after consumption | It will be evaluated at each of the visits and in the month of follow-up will be evaluated with a daily diary. |
| Concomitant medication | Day 1, at 4, 8 and 12 weeks later | The change in the use of medications will be evaluated. It will be evaluated at each of the visits and in the month of follow-up will be evaluated with a daily diary. |
| Dietary survey | Day 1, at 4, 8 and 12 weeks later | Three days will be evaluated (two weekdays and one weekend day). |
| Body weight | Day 1, at 8 weeks later | Bioimpedance, in Kg. For this we will use a TANITA |
| Liver safety variables | It will be measured twice, once at baseline or at the end of the consumption after 8 weeks. | It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L) |
| Gut microbiota | Day 1, at 4, 8 and 12 weeks later | Evaluated with stool sample |
Countries
Spain
Outcome results
None listed